San Francisco, CA – May 13, 2025 – VeriSIM Life, a trailblazer in artificial intelligence (AI)-powered drug development, is proud to announce that its Founder and CEO, Dr. Jo Varshney, has been named to the 2025 “100 Women in AI” list by Flybridge Capital Partners and XFactor Ventures.
The prestigious list honors women who are making groundbreaking contributions across the AI ecosystem, shaping the future of technology, business, and society. Dr. Varshney joins an elite group that includes luminaries such as Dr. Fei-Fei Li, Mira Murati, and some of the most influential leaders in modern AI. A celebration recognizing all 100 honorees will take place on Tuesday, April 8, 2025, in New York City.
Dr. Varshney’s selection underscores her visionary leadership and transformative impact at VeriSIM Life, where she has led the development of BIOiSIM®, a first-in-class AI-powered simulation platform for translational drug development. Her biology-first approach to machine learning is accelerating how life-saving treatments are discovered, optimized, and delivered, reducing costs, minimizing risk, and improving the predictability of clinical success.
“I am truly honored to be recognized alongside such an inspiring group of women who have advanced the frontiers of AI,” said Dr. Varshney. “This award highlights not only our team’s groundbreaking work at VeriSIM Life, but also the importance of bringing diverse perspectives into scientific innovation—especially in a field where lives are on the line.”
Her inclusion reflects the increasing recognition of women driving change across AI and the critical importance of inclusivity in building the future of medicine and technology.
About VeriSIM Life
VeriSIM Life is transforming drug development through its proprietary AI-powered platform, BIOiSIM®. This advanced computational engine simulates human and animal biology to better predict the clinical success of drug candidates in early development. By reducing unnecessary testing and streamlining decision-making, BIOiSIM® drastically improves capital efficiency and reduces time to market for new therapies. To learn more, visit www.verisimlife.com.
AtlasGEN Novel Drug Designer efficiently identifies new molecules based on favorable chemical properties and simultaneously evaluates them for clinical safety and effectiveness based on biology using VeriSIM Life’s groundbreaking Translational Index™ technology.
Iterative ranking of target engaging hits by their Translational Index values reduces the time and cost associated with other computational hit discovery approaches, while compressing the hit-to-lead refinement and optimization process by pre-validating hits for translatability. This unique integration dramatically reduces the number of compounds to evaluate in subsequent experimental research.
The ability to generate target engaging compound hits depends largely on the size of the molecular search library. The AtlasGEN search space is supported by more than 1 trillion compounds. Generative AI and deep learning techniques deliver unprecedented discovery capability.
AtlasGEN accurately predicts protein-lygand binding affinity by combining geometric conformer analysis with machine learning based on experimental data 72% more efficiently than molecular docking-based approaches.
.png)
